Servier drug Tibsovo is now approved for treating advanced cases of myelodysplastic syndrome that have an IDH1 mutation. It’s the first approval of a targeted therapy for this type of cancer.
Agios Pharmaceuticals has garnered one recent FDA approval and has five other pivotal trials underway. Click here to read a full analysis of AGIO stock.
NewsNow: Leukaemia news | Breaking News & Search 24/7 newsnow.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newsnow.co.uk Daily Mail and Mail on Sunday newspapers.